Sumatryptan + naproksen: interakcje

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Amfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (etykieta leku Apiksaban, Ostrzeżenie w ramce)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina, Interakcje z innymi lekami)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina + nalokson, Interakcje z innymi lekami)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (etykieta leku Buspiron, Ostrzeżenia)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Interakcje z innymi lekami)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Butorfanol, Środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (etykieta leku Cydofowir, Interakcje z innymi lekami)

Immediately discontinue concomitant treatment with TONMYA and a serotonergic agent if serotonin syndrome symptoms occur and initiate supportive symptomatic treatment. (etykieta leku Cyklobenzapryna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (etykieta leku Dabigatran, Ostrzeżenie w ramce)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (etykieta leku Deksamfetamina, Ostrzeżenia)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Łączenie dziurawca z lekami przeciwdepresyjnymi i innymi lekami serotoninergicznymi zwiększa ryzyko zespołu serotoninowego. (NCCIH, St. John's Wort)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (etykieta leku Edoksaban, Ostrzeżenie w ramce)

Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (etykieta leku Efawirenz + lamiwudyna + tenofowir, Ostrzeżenia i środki ostrożności)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Ostrzeżenia i środki ostrożności)

…the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (etykieta leku Enoksaparyna, Ostrzeżenie w ramce)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (etykieta leku Fondaparynuks, Ostrzeżenie w ramce)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (etykieta leku Granisetron, Ostrzeżenia i środki ostrożności)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon, Interakcje z innymi lekami)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + chlorfenamina, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + homatropina, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + paracetamol, Środki ostrożności)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydromorfon, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Kodeina, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Leworfanol, Środki ostrożności)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Lisdeksamfetamina, Ostrzeżenia i środki ostrożności)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (etykieta leku Lit, Ostrzeżenia i środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Metadon, Ostrzeżenia i środki ostrożności)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etykieta leku Metaksalon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Metamfetamina, Ostrzeżenia i środki ostrożności)

Methotrexate Clinical Impact: Concomitant administration of some NSAIDs with high-dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (etykieta leku Mirtazapina, Ostrzeżenia i środki ostrożności)

MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (etykieta leku Mizoprostol, Ostrzeżenie w ramce)

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (etykieta leku Montelukast, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Morfina, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etykieta leku Oksykodon, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Oksymorfon, Interakcje z innymi lekami)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Olicerydyna, Interakcje z innymi lekami)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (etykieta leku Ondansetron, Ostrzeżenia i środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etykieta leku Palonosetron, Ostrzeżenia i środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Paracetamol + kodeina, Środki ostrożności)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Pentazocyna + nalokson, Środki ostrożności)

‎ • Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Petydyna, Ostrzeżenia i środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Pokrzyk wilcza jagoda (belladonna) + opium, Interakcje z innymi lekami)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (etykieta leku Pralatreksat, Interakcje z innymi lekami)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (etykieta leku Prasugrel, Ostrzeżenie w ramce)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Prometazyna + kodeina, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Remifentanyl, Ostrzeżenia i środki ostrożności)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (etykieta leku Rywaroksaban, Ostrzeżenie w ramce)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Tapentadol, Ostrzeżenia i środki ostrożności)

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (etykieta leku Tenofowir, Ostrzeżenia i środki ostrożności)

History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (etykieta leku Trazodon, Ostrzeżenia i środki ostrożności)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (etykieta leku Wortioksetyna, Ostrzeżenia i środki ostrożności)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7)]. (etykieta leku Sumatryptan + naproksen, Przeciwwskazania)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etykieta leku Zyprazydon, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (etykieta leku Adefowir, Ostrzeżenia i środki ostrożności)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (etykieta leku Afatynib, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (etykieta leku Anagrelid, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (etykieta leku Cefotaksym, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (etykieta leku Chlorek potasu, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Cyclosporine Clinical Impact: Concomitant use of NSAIDs and cyclosporine may increase cyclosporine’s nephrotoxicity. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (etykieta leku Cyprofloksacyna, Interakcje z innymi lekami)

Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (etykieta leku Cytrynian potasu, Interakcje z innymi lekami)

…↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (etykieta leku Dapagliflozyna, Interakcje z innymi lekami)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (etykieta leku Deferazyroks, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (etykieta leku Desmopresyna, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Digoxin: Concomitant use with sumatriptan and naproxen sodium tablets can increase serum concentration and prolong half-life of digoxin. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Donepezyl, Ostrzeżenia i środki ostrożności)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. (etykieta leku Droksydopa, Interakcje z innymi lekami)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (etykieta leku Drospirenon + etynyloestradiol, Ostrzeżenia i środki ostrożności)

Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (etykieta leku Elwitegrawir + kobicystat + emtrycytabina + tenofowir, Ostrzeżenia i środki ostrożności)

Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (etykieta leku Emtrycytabina + tenofowir, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (etykieta leku Erlotynib, Ostrzeżenia i środki ostrożności)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (etykieta leku Febuksostat, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. (etykieta leku Flukonazol, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Naproxen Coadministration (N=18) of naproxen sodium capsules (250 mg) with NEURONTIN (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%. (etykieta leku Gabapentyna, Interakcje z innymi lekami)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (etykieta leku Glibenklamid, Interakcje z innymi lekami)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (etykieta leku Glimepiryd, Interakcje z innymi lekami)

…angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (etykieta leku Glipizyd, Interakcje z innymi lekami)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (etykieta leku Glipizyd + metformina, Środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (etykieta leku Itrakonazol, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (etykieta leku Kwas alendronowy, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (etykieta leku Kwas ibandronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (etykieta leku Lewofloksacyna, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Memantyna + donepezyl, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (etykieta leku Mifepryston, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (etykieta leku Moksyfloksacyna, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (etykieta leku Nalbufina, Interakcje z innymi lekami)

Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (etykieta leku Nateglinid, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (etykieta leku Nintedanib, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (etykieta leku Ofloksacyna, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (etykieta leku Pentoksyfilina, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (etykieta leku Pioglitazon + glimepiryd, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Rywastygmina, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (etykieta leku Tofacytynib, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Risk: Potentially life-threatening condition could result from use of Tramadol Hydrochloride Extended-Release Capsules, particularly during concomitant use of serotonergic drugs. (etykieta leku Tramadol, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Risk Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol, including tramadol hydrochloride and acetaminophen, during concomitant use with serotonergic drugs. (etykieta leku Tramadol + paracetamol, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Perform a cardiovascular evaluation in patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan and naproxen sodium tablets. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (etykieta leku Upadacytynib, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Drugs that Interfere with Hemostasis (e.g. warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking sumatriptan and naproxen sodium tablets with drugs that interfere with hemostasis. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (etykieta leku Sumatryptan + naproksen, Interakcje z innymi lekami)

NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (etykieta leku Worykonazol, Interakcje z innymi lekami)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (etykieta leku Fentermina, Ostrzeżenia i środki ostrożności)

…angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (etykieta leku Finasteryd, Interakcje z innymi lekami)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (etykieta leku Glibenklamid + metformina, Interakcje z innymi lekami)

In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (etykieta leku Infliksymab, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (etykieta leku Lenalidomid, Ostrzeżenia i środki ostrożności)

Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (etykieta leku Lewotyroksyna, Interakcje z innymi lekami)

Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (etykieta leku Liotyronina, Interakcje z innymi lekami)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Serotonin syndrome may occur with sumatriptan and naproxen sodium tablets, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Contraindications (4) and Drug Interactions (7.1)] . (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (etykieta leku Sumatryptan + naproksen, Ostrzeżenia i środki ostrożności)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (etykieta leku Pilokarpina, Interakcje z innymi lekami)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (etykieta leku Repaglinid, Interakcje z innymi lekami)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (etykieta leku Tocilizumab, Interakcje z innymi lekami)

Drug-drug interaction studies in healthy subjects have been conducted with zileuton immediate-release tablets and digoxin, phenytoin, sulfasalazine, and naproxen. (etykieta leku Zileuton, Interakcje z innymi lekami)